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Abstract
Background: In spite of efforts to employ risk-based strategies to increase monitoring efficiency in the academic
setting, empirical evidence on their effectiveness remains sparse. This mixed-methods study aimed to evaluate the
risk-based on-site monitoring approach currently followed at our academic institution.
Methods: We selected all studies monitored by the Clinical Trial Unit (CTU) according to Risk ADApted MONitoring
(ADAMON) at the University Hospital Basel, Switzerland, between 01.01.2012 and 31.12.2014. We extracted study
characteristics and monitoring information from the CTU Enterprise Resource Management system and from
monitoring reports of all selected studies. We summarized the data descriptively. Additionally, we conducted
semi-structured interviews with the three current CTU monitors.
Results: During the observation period, a total of 214 monitoring visits were conducted in 43 studies resulting in
2961 documented monitoring findings. Our risk-based approach predominantly identified administrative (46.2%)
and patient right findings (49.1%). We identified observational study design, high ADAMON risk category, industry
sponsorship, the presence of an electronic database, experienced site staff, and inclusion of vulnerable study
population to be factors associated with lower numbers of findings. The monitors understand the positive
aspects of a risk-based approach but fear missing systematic errors due to the low frequency of visits.
Conclusions: We show that the factors mostly increasing the risk for on-site monitoring findings are
underrepresented in the current risk analysis scheme. Our risk-based on-site approach should further be
complemented by centralized data checks, allowing monitors to transform their role towards partners for
overall trial quality, and success.
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Background
Adherence to the International Conference on
Harmonization of Good Clinical Practice (ICH GCP)
guidelines should ensure the safety, rights, and integrity
of trial participants as well as the confidentiality of per-
sonal information and data quality [1]. Trial monitoring
through trained clinical monitors is requested by ICH
GCP, but the guideline provides limited insight on the
procedures of quality assessment during such monitoring
visits [2, 3]. Traditional approaches relied on intensive on-
site visits and 100% source data verification (SDV)
irrespective of the risk levels in the study, which have been
associated with high cost and limited contribution to
clinical trial data quality [4–6].
Recent developments at international bodies and regula-
tory agencies such as the European Medicines Agency
(EMA) have supported the need for risk-proportionate ap-
proaches to clinical trial monitoring [7–9]. In November
2016, the ICH published the final version of the integrated
addendum to ICH-GCP, advising Sponsors to develop a
systematic, prioritized, risk-based approach to monitoring
clinical trials [3]. Similarly, the forthcoming European
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Union (EU) Clinical Trial Regulation will permit reduced
monitoring for low-risk intervention trials [10]. Among
the first, the Risk ADApted MONitoring (ADAMON)
Project proposed an instrument for the facilitation of risk
analysis allowing on-site monitoring strategy tailored to
the risk profile of every trial [11]. Risk analysis thereby
refers to the risk of jeopardizing patient safety and rights
or the validity of results and considers patient, site, and
study design robustness-related indicators. Furthermore,
risk analysis takes into account the risks of the study inter-
vention compared to the risks a patient would run if
treated in routine practice. This approach was first pro-
posed in 2009 and later adapted by other stakeholders
such as the Organization for Economic Co-operation and
Development (OECD), the U.S. Food and Drug Agency
(FDA), and EMA [9, 12, 13]. It encouraged study sponsors
to assess, on a case-per-case basis, the risk associated with
an individual trial protocol, implement risk assessments
that focus on critical data and procedures, and utilize
alternative monitoring approaches taking advantage of the
increasing use of electronic systems. Sponsors should
develop a monitoring plan that describes, based on the
risk assessment, the monitoring strategy, the monitoring
responsibilities of all the parties involved, the various
monitoring methods to be used, and the rationale for their
use [3]. However, in the absence of credible data to de-
scribe impact of a change of monitoring approach on data
quality and study cost, the majority of industry-sponsored
trials continue to be monitored using a traditional moni-
toring approach with up to 100% SDV. It has been esti-
mated that SDV can consume up to 25% of the sponsor’s
entire clinical trial budget, even though the association be-
tween data quality/subject safety and the extent of moni-
toring and SDV has not been clearly demonstrated [14].
Financial estimates of a single monitoring site visit range
from US$800 in 1991 to US$1500 in 2009 [15, 16], with
conservative cost estimates for one single query of
US$150 [17]. The approach taken may therefore be evalu-
ated as overcautious at best, and at worst, a complete
waste of resources based on current reviews [18, 19].
In the academic setting, restricted resources often oblige
investigators to apply a risk-based approach to trial moni-
toring which is expected to be less labor intense [20]. At
the academic Clinical Trial Unit (CTU) at the University
Hospital in Basel, Switzerland, we have applied risk-based
on-site monitoring based on the ADAMON project for all
patient-oriented research projects since 2012. In order to
understand the implications of this approach for patient
safety and data quality at our institution, we undertook
this mixed-method investigation. The aim of our study
was to i) retrospectively investigate the characteristics of
findings documented during on-site visits, ii) identify key
factors that might influence the number and types of
monitoring findings, iii) assess the costs associated with
our approach, and iv) understand the experience of our
monitors and the challenges they face.
Methods
Setting
This mixed-method study was performed at the CTU of
the University Hospital in Basel. The CTU offers moni-
toring services to investigator- and industry-initiated
studies conducted at our institution and affiliated sites if
desired by sponsors. CTU monitors are qualified by
training and experience and work according to clearly
defined standard operating procedures (SOPs) which are
reviewed and updated by an autonomous quality-
assurance officer on a regular basis. The risk evaluation
adopted by the CTU (Table 1) includes a structured trial
risk classification by the project manager according to
the ADAMON project and the Swiss Human Research
Act as described by the Swiss Clinical Trial Organization
[21]. This approach allows the categories low, medium,
or high risk; and the assessment of additional three risk
modulators (Table 1). These risk modulators may lower
or raise the risk within a certain risk category and there-
fore influence the duration of site visits, but not their
frequency. After risk classification, the project manager
specifies the extent and nature of on-site monitoring
visits in the monitoring plan (Table 2). CTU monitors
then conduct on-site monitoring visits according to the
pre-specified monitoring plan and document monitoring
findings in monitoring reports which are shared and dis-
cussed with both the sponsor and the project manager.
Quantitative retrospective analysis
We included all investigator-initiated trials (IITs) and
industry-sponsored studies monitored by the CTU
between January 1st 2012 and December 31st 2014 with
the exception of studies for which monitoring had never
been fully initiated (i.e. <10% of planned working hours
completed because of an early study discontinuation or
delayed study start). Since the introduction of risk-based
monitoring at our institution in 2012, a total of six
monitors had been involved in monitoring activities. For
all included studies, we extracted a set of variables
covering detailed characteristics at the level of the study
itself, the level of the study site and the individual moni-
toring visit.
Study-specific variables included
– study design,
– study type,
– study sponsor,
– type of research,
– study phase (I-IV), and
– type of study population (e.g. inclusion of vulnerable
populations).
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Variables covering study site information included
– site location,
– ADAMON risk category,
– presence of electronic database,
– principal investigator, and whether he/she changed
during conduct,
– staff experience, and
– number of planned patients at the site.
At the level of the individual monitoring visit we ex-
tracted information on
– type of visit (i.e. initiation, interim, close-out),
– the number of
– administrative,
– patient rights,
– patient safety,
– laboratory/biological specimen,
– data point confirmation, and
– endpoint related findings.
Extraction and categorization of findings was per-
formed independently and in duplicate (AO, MV, CB)
from monitoring plans and reports using a validated
web-based database (secuTrial®). Classification of find-
ings corresponded to the main categories used in our
monitoring reports and categories were treated as mutu-
ally exclusive. Table 6 provides examples of findings for
each category. Discrepancies between extractors in clas-
sifying the variables were resolved through discussion by
the extractors. After an initial calibration phase, agree-
ment between the extractors was considered “good” if
no more than four out of 49 extracted variables differed.
Findings that were corrected immediately on-site were
often not documented and therefore not included in our
study. We summarized the number of findings descrip-
tively, stratified by key variables and graphically dis-
played as i) total findings per study (or site, depending
on the variable), ii) percentage of administrative or pa-
tient right findings out of total number of findings. Fig-
ures were interpreted visually. Furthermore, we collected
information on human and financial resources employed
for monitoring activities from the CTU Enterprise Re-
source Management (ERP) system for each project. We
calculated total resource use by summing the total hours
worked by our monitors during the analyzed time period
(2012–2014), as retrieved from the ERP, multiplied by
the hourly salary rate. We then divided the total human
resource cost by total number of findings which we had
documented and extracted from monitoring reports.
Semi-structured interviews
We interviewed three monitors who were involved in
these monitoring visits and who continue to work at our
institution at present. The main themes covered during
these interviews were i) monitors’ perspective on risk-
based monitoring per se, ii) the practical settings in which
these visits and findings of events were documented, iii)
the challenges they faced during these visits, and iv) their
perspectives on the future development of risk-based
monitoring. As interviews did not include health-related
data and were therefore not within the scope of the applic-
able Human Research Act (HRA, Art.1), we did not re-
quire formal ethical approval. Each interview was
conducted in German by NR, tape recorded with the
monitor’s permission, transcribed in full, and anonymized
at the level of transcription. We examined all the tran-
scripts in duplicate (BvN and NR) and BvN coded each
interview. We then grouped codes into clusters around
similar and interrelated themes until we reached consen-
sus. In the results section below, we will describe and dis-
cuss three key themes that emerged from our qualitative
interviews (a) factors influencing risk-based monitoring
findings; (b) the monitoring process and the challenges
faced; and (c) the current role of monitors and future
perspectives.
Results
Study sample characteristics
We included forty-three studies (39 investigator-initiated,
three industry-sponsored) monitored between January 1st
2012 and December 31st 2014 for analysis. Characteristics
of these studies are shown in Table 3, study stratification
by risk categories and associated risk factors in Table 4.
Characteristics of monitoring findings
In total, we documented 2961 findings during 214 moni-
toring visits in 43 studies between 2012 and 2014 (Tables 5
and 6). In ten out of 43 studies, we monitored more than
Table 2 Recommended on-site monitoring activities based on study risk classification. Informed Consent (IC)
Risk of Study Initiation visit Interim visit Content of interim visits Close out visit
Low optional after first patients, then
adaptable (e.g. 1/year)
Endpoints (extent to be defined),
IC (usually 100%)
optional
Intermediate mandatory after first patients, then
adaptable (e.g. 1/year)
Endpoints (extent to be defined),
IC (usually 100%), safety (usually 100%)
mandatory
High mandatory after first patients, then
in regular intervals
Endpoints (extent to be defined),
IC (usually 100%), safety (usually 100%)
mandatory
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one site. Overall, administrative findings (46.2%; e.g.
missing CVs or incomplete Investigator Site Files etc.)
were equally predominant as patient rights findings
(49.1%; e.g. wrongly signed and dated informed consent
forms), whilst patient safety issues were found only excep-
tionally (1.1%). Although the studies varied in their total
amount of findings, we documented at least one adminis-
trative and one patient right finding in almost every study,
and at least one safety finding in a fifth of all studies
(Tables 5 and 6). The remaining findings included issues
related to laboratory procedures or biological specimen
(2.3%), and issues related to the endpoint which could not
be clarified with staff at site and required written confirm-
ation (e.g. clarification of a questionable laboratory value
which seemed out of range, 1.2%) (Table 5).
Influencing factors on number and type of findings
Generally, the sample size of a study was positively as-
sociated with the total number of findings (Fig. 1). Due
to the low number of other than administrative and pa-
tient rights findings, the figures display both the
percentage of patient rights (X %) and administrative
findings (100–X %). Visual inspection of figures showed
that factors such as observational study design (Fig. 2a,
b), high ADAMON risk category (Fig. 3b), industry
sponsorship (Fig. 3c), the presence of an electronic
database (Fig. 3d), experienced site staff (Fig. 3e), and
inclusion of vulnerable study population (Fig. 3f ) were
associated with lower numbers of monitoring findings.
As a trend, studies sponsored by industry or with a high
risk category tended to result in less patient rights find-
ings compared to other studies, for which the propor-
tion pattern (patient rights vs. administrative) varied
widely (Figs. 3b, c).
Although observational studies generally resulted in
fewer findings, two of the nine analyzed studies were
outliers (>400 findings/study) (Fig. 2a, b). One was a
multicenter study including seven sites but no electronic
data capture system, resulting in a total of 413 findings
(45.8% administrative, 49.6% patient rights) in seven
Table 4 Study sample by risk categories and associated risk
factors
Total
n %
Total studies 43 100
ADAMON risk category Low 11 25.6
medium 23 53.5
High 9 20.9
Total 43 100
Electronic database present
at first patient in
Yes 19 44.2
No 24 55.8
Total 43 100
Principal Investigator change
during study
Yes 3 7.0
No 40 93.0
Total 43 100
Vulnerable study populationa Yes 7 16.3
No 36 83.7
Total 43 100
Total sites 94 100
Staff experiencedb, by site Yes 88 93.6
No 6 6.4
Total 94 100
Staff change, by site Yes 11 11.7
No 48 51.1
Unknown 35 37.2
Total 94 100
Study sample including 43 studies monitored by the CTU Basel between 2012
and 2014, stratified by ADAMON risk categories, and factors associated with
risk evaluation
aDefined as “children, adolescents, adults lacking capacity in the consent
procedure, pregnant women and in-vitro fertilized embryos and fetuses,
prisoners, and subjects in emergency situations” (according to HRA, Chapter 3)
bDefined as a) GCP trained, b) solely dedicated to research activities (e.g. a study
nurse, resident, etc.), and c) has been involved in the conduct of one or more
clinical research studies before
Table 3 Study sample characteristics (number, %)
Total
n %
Total studies 43 100
Study design Interventional 34 79.1
Observational 9 20.9
Study type Multicenter 10 23.3
Singlecenter 33 76.7
Study sponsor Investigator (academic) 40 93.0
Industry 3 7.0
Type of research Drug 29 67.4
Medical Device 5 11.6
Biological Samplesa 4 9.4
Otherb 5 11.6
Study phase
(drug studies, n = 29)
I 9 31.1
II 7 24.1
III 8 27.6
IV 3 10.3
Otherc 2 6.9
Study sample including 43 studies monitored by the CTU Basel between 2012
and 2014
aBiological samples incl. physiological or genetic analysis of human biological
samples (e.g. urine, blood, tissue, etc.)
bOther incl. observational research, health economics assessments, or tissue-
based intervention/stem-cell transplantation
cOther incl. cost-effectiveness trials not specific to a phase
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initiation, seven interim one, and five interim two visits.
The second study was a large single center study (>2,000
planned patients) with inexperienced study personnel
and principal investigator. No initiation visit was per-
formed given the low risk character of the study and an
electronic data capture system was not available. In this
study, four interim visits resulted in a total of 710 find-
ings of which 20.1% were administrative and 75% were
related to patient rights issues (Fig. 2b, largest red cir-
cle). In addition, both studies experienced a change in
monitor, after which the overall number of findings
increased.
Out of 43 monitored studies, 39 were monitored more
than once (at least one site), and 12 were monitored at
least three times (at least one site) (Additional file 1: Fig-
ure S1a). Thereof, 11 studies had an initiation visit and
four studies experienced a change in monitor through-
out the study. Generally, findings tended to decrease
after the second interim visit. One study increased in
findings after the third visit which was due to a new ver-
sion of the informed consent which was not adequately
used in all patients. The proportion of administrative
findings was high at initiation but showed a decrease
during the conduct of the study, whereas patient rights
findings increased. (Additional file 1: Figure S1b, c).
In our sample, only three sites conducted three or
more different studies within the given two-year time
period (Additional file 1: Figure S2; site 1: studies 3, 4, 8,
and 9; site 2: studies 22, 23, 33, and 36; site 3: studies 26,
21, and 32). Factors such as study design (interventional
vs. observational), study type (e.g. phase 1–3), sample size,
the risk associated with the studies performed (and there-
fore the associated monitoring risk category), and staff ex-
perience does usually not differ much within a given site,
and visual inspection did not reveal a major difference in
total number of findings within trials at each of the three
sites (Additional file 1: Figure S2). However, the men-
tioned characteristics differed significantly across the three
sites (one high risk pharmacological phase 1 unit, one low
risk observational cardiology unit, and one medium risk
cognitive neuroscience unit) and did therefore not allow
for comparison between these sites. In the ten multicenter
studies included in our sample (1, 7, 12, 14, 16, 19, 21, 26,
31, and 32 in Additional file 1: Figure S2), no trend in total
number of findings across sites could be identified.
Table 5 Characteristics of monitoring findings
Total
n %
Total Studies 43 100
Total Monitoring Visits 214 100
Findings
Administrative 1367 46.2
Patient rights 1453 49.1
Patient safety 32 1.1
Laboratory/biol. specimen 70 2.3
Endpoint related data point:
confirmation requested
36 1.2
Endpoint related data point:
Data point changed
3 0.1
Total 2961 100
Average n findings/visit 13.8
Studies with
at least 1 administrative finding 43 100
at least 1 patient right finding 41 95.3
at least 1 patient safety finding 9 20.9
Sum of findings by CTU monitors in total (number, %). Note: Findings which
were resolved on-site between monitor and study staff and not documented
in monitoring reports are not listed.
Table 6 Examples of monitoring findings
Finding category Examples of findings
Administrative • Changes at the investigational site (staff
training, staff CVs, address, technical
equipment, etc.) not documented
• Functions and responsibilities log not up
to date
• Subject related logs not up to date
• CRFs not available at site and/or not
documented by authorized staff
Patient rights • Informed Consent Forms not signed and/or
not dated correctly
• No valid and approved version of Informed
Consent Form used
• Amendments/addenda to Informed Consent
Form not communicated to patients and no
re-consent obtained
• Patient did not fulfill all inclusion criteria
Patient safety • No description of the process for detecting
and reporting serious and unexpected adverse
events and/or unanticipated problems
involving risk to participants in place at site
• Adverse events not correctly documented
and/or reported as required (e.g. to Sponsor,
EC, Competent Authority)
• New safety information not approved by
authorities
• Staff not trained according to new safety
information
Laboratory/Biological
Specimen
• Biological specimen not stored correctly
according to protocol
• Process conducted not in accordance with
Good Manufacturing Practice (GMP)
Data point confirmation
requested
• Indicates whether finding challenges the
credibility of data point, e.g. by stating “Please
confirm that blood pressure measure is
100/65 mmHg”
Data point changed • Indicates whether data point was adjusted as
direct consequence of finding, e.g. “Blood
pressure of 100/65 mmHg was corrected to
120/80 mmHg”
CV Curriculum Vitae, CRF Case Report Form, EC Ethics Committee
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Cost of monitoring
Data on monitoring costs were only available since May
2012, when an electronic enterprise resource manage-
ment system was implemented at the CTU. Overall, cost
data was available for 33 out of 43 monitored projects.
For these projects, we documented a total of 4320 work-
ing hours for 2401 monitoring findings. With an hourly
salary rate of US$92.5 this translated into total personnel
costs of US$ 399’280 and an average per findings cost of
US$166. In this estimate, however, the endpoint related
findings that were resolved on-site are not considered,
leading to potential overestimation of costs per finding.
The Monitor’s perspective
In addition to evaluating the characteristics of findings of
our on-site visits, we aimed to understand the practical
experience of monitors involved, challenges they face dur-
ing monitoring, their perspectives on the risk-based ap-
proach, and suggestions for improvement.
Three monitors we interviewed had been working as
clinical trial monitors for two to 21 years, two of them
mainly in the academic setting whereas the third one
mainly in the pharmaceutical industry environment. With
the introduction of risk-based monitoring at the CTU in
2012, all three participants started to monitor according
to the above described standard procedure. Below we de-
scribe three main themes from these interviews and pro-
vide select quotations for each.
Factors influencing risk-based monitoring findings
All three monitors expressed a generally positive attitude
towards the concept of upfront risk evaluation, which al-
lows assessment of critical factors in the study design or
practical challenges that the study team might face while
implementing the trial as described by one of our
monitors.
“The positive effect clearly is that you think more
about the study itself. If you take the effort to classify
the study by risk factors you can actually eliminate
many things upfront. Because of that evaluation, I
know what to set value on when I open a site”.
(Monitor III)
The factors that the monitors in general deemed
crucial for low numbers of findings in trials were profes-
sional, trained and motivated study personnel, together
with a robust study design and rigorous planning of a
study. These factors were also attributed to support par-
ticipant recruitment into the trials and eventual success
of the trial. Monitor III argued that indicators related to
the study site were underrepresented in the ADAMON
risk evaluation, in spite of the fact that they have signifi-
cant influence on the way trials are conducted. Other
factors that the monitors believed to contribute posi-
tively to overall trial quality and success were the quality
of the study protocol, the early involvement of monitor
and study nurses in protocol development, training and
experience of all personnel involved, planning of fi-
nances and infrastructure before trial begins, available
resources, trial coordination and management, assign-
ment of clear responsibilities, well planned recruitment,
and clear and transparent communication among all
stakeholders involved as elaborated in the quote below.
“But it all depends on the experience of staff on-site,
if they have lots of experience with studies, they know
how to do it. But don’t forget that staff changes so
often at the site, you never get the same people from
the start until the end of a study. The new ones, how
will they be trained? We as monitors only hear about
it half a year later and if you only visit them once a
year, you hear that they have changed the recruiting
physician and that patients have been informed
wrongly for three quarters of a year.“(Monitor III)
Monitoring process and challenges faced
With respect to what the current risk-based approach is
able to cover on-site, all monitors came up with two
distinct topics, namely patient safety and rights, and data
quality. Monitor I and II felt that minimum aspects of pa-
tient safety and rights, incl. informed consent forms and
inclusion/exclusion criteria, but also “crucial” data points
such as the primary endpoint, were mostly covered by
their on-site visits. Two monitors did not see any issues
related to patient safety or their rights with the current ap-
proach as described below.
Fig. 1 Studies according to the planned sample size and the final
total number of monitoring findings (log scale)
von Niederhäusern et al. BMC Medical Research Methodology  (2017) 17:26 Page 7 of 15
“It depends on the monitoring plan; usually we look at
100% of the Informed Consent Forms, unless there are
too many patients such as in cohort studies. We
always look at the inclusion and exclusions criteria.
Endpoints are to be discussed and defined with the
principal investigator. Depending on the budget
available, we might also look at the Trial Master File,
and then I am done in no time” (Monitor I)
“I hope that I cover safety aspects with my monitoring.
Actually I don’t see any issues with it. There is no
monitoring plan without the safety aspect, usually it is
100% covered. (…) Depending on what you find, you
adapt it (the monitoring plan). If you find critical
issues, for example a Serious Adverse Event that was
not documented, you tell the team (on-site) to look at
the other patients’ data and check whether they were
correct.” (Monitor II)
However, Monitor III expressed concerns about rather
infrequent on-site visits with long time gaps in between
during which there was a clear risk of missing patient
safety or patient rights aspects in particular. He also
feared that these findings would then get resolved only
during the next visit which might be after six months.
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“I question whether this approach is compatible with
GCP. According to GCP you put patients first, and
then the scientific question. There you also include
data protection and the ICF (informed consent form).
You don’t really respect patient rights if, for example,
a wrong ICF version was signed and I only notice after
half a year, just because the study is a low risk study
according to the evaluation. I don’t think it affects the
scientific validity, but more the patient safety and
rights aspects”. (Monitor III)
With respect to data quality, all monitors mentioned
“systematic data errors”, i.e. errors that are not produced
by chance. They were concerned to miss systematic errors
with the risk-based approach. Monitor I sometimes pre-
ferred to monitor more frequently in order to identify sys-
tematic data errors as and when they occurred. Monitor I
and II would like to rather cover 100% source data for
fewer patients than single puzzle pieces of several patients
to be able to pick up systematic errors as described in
quote below.
a
c
e
b
d
f
Fig. 3 Total number of findings and proportion of patient rights findings in studies stratified by a study type, b ADAMON risk category, c study
sponsor, d studies with vs. without electronic database, e studies conducted at sites with vs. without clinical research experience, f studies with
vs. without vulnerable study population. Diameter of circles proportionate to total number of findings per study (a, c, d, f) or per site (b, e)
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“One is for sure, if you don’t see that mistake at the
beginning, it’s going to repeat with the next patients.
So that’s a systematic error then, and of course data
quality suffers! “(…) “If I knew that every three month
there is a monitor at your doorstep who wants to
critically look at your data, then I am of course
required to get my stuff done in time and…a bit more
accurate as if, you know, I know that there is anyways
no one looking at my data. Then you get the running
around after the data at the end of the year”.
(Monitor III)
Monitor II further questioned low importance given to
“less important data points” (e.g. lab values not specified
as outcome variables). These “less important data points”
are not considered in the risk-based monitoring plan
according to ADAMON and therefore not checked by the
monitors
“Often, we do not look at lab values because they
are not seen as risky values, maybe only 10% is
seen as crucial for the primary endpoint. But then
you ask yourself whether you wouldn’t miss
transcription errors if you don’t look at these
values at all. (…) There are not only systematic
errors that you don’t see but also those that
appear everywhere and they’re even more difficult
to detect. And it also depends on the format in
which you collect data, if it is on paper or not.
The CRF (case report form) heavily influences the
number of mistakes that are made, and you don’t
look at all of these with the risk-based approach.
(…) If you, for example, look at one patient 100%
in a study and not the others, you of course detect
systematic errors and point to that and make them
look at the other patients in their documentation as
well.” (Monitor II)
All monitors believed that data quality would improve
with increased frequency of monitoring. Monitor I and
III disagreed with the current guidelines that in some
low-risk cases, an initiation visit is not necessary. They
would rather leave out the close-out visit but always
perform an initiation visit to train the personnel on cru-
cial GCP and study-related aspects.
“I assume that in an inspection, you know, if they were
to look at 100% of the data after my monitoring, they
would find errors even in my monitored data. But I
am sure you see exactly what documents were
monitored and which weren’t. (…) but I believe that
data quality would for sure be better with more
monitoring, there I am 100% sure.” (Monitor I)
“Also the change in personnel has an influence, if you
don’t take care of the training of new employees, and
you don’t involve them. The situation on-site is not
reflected adequately in ADAMON, it’s more sort of a
weak factor, that if you’re there anyways, you monitor
longer, but it doesn’t influence the frequency of
monitoring. Changes and structures on-site should
have a stronger influence on the frequency of visits,
in my opinion. “(Monitor III)
Monitor III further questioned whether in reality the
risk-based approach proves cost-effective if many errors
were missed in between visits due to the low frequency
of visits and when amendments are needed to correct
those.
“It is not clear whether it is cheaper if the monitor visits
less frequently and everything on-site goes downhill or if
it wasn’t better if the monitor had visited once or twice
more, you know. To make crappy data better again is
also not cheap, right? Even if you adapt all ADAMON
criteria, we should get away from only seeing cost sav-
ings in it. “(Monitor III)
When monitors were further asked about why the
frequency of monitoring visits could not be adapted in
cases where needed, all mentioned the difficult financial
environment in which academic trials are conducted. In
their experience, most often, funding limitations were
the main factor for restrictions in the amount and
frequency of monitoring visits that could be performed,
rather than the actual risk categorization.
“…just because the budget doesn’t allow, you know, I
would like to monitor more frequently or follow the
risk classification more strictly, but you can’t, because
of the financial limitations.” (Monitor I)
Role of monitors and future perspectives
We explored further monitors’ views on ways to improve
monitoring process and to make it cost effective. All mon-
itors discussed few possibilities especially in defining their
role as monitors and the way they are perceived by the
study teams. They would like to be seen as trustworthy
partners who assist in ensuring trial success and quality
instead of being mere “controllers”. They hoped that prin-
cipal investigators would be more familiar with their role
and study teams will not see them as a “necessary evil”
who consume significant part of the study budget and
with whom they have to deal with, but rather as support-
ing partners who assist in achieving the study goals and
ensure study quality. They see themselves as critical exam-
iners, a fresh pair of eyes, who provide constructive
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feedback to the study team, as trusted supporters, facilita-
tors of communication across sites, and motivators.
“I would wish for more acceptance of monitoring, they
all think it is just a necessary evil. That you don’t do it
because it’s important and helps data quality, but only
because the regulators and authorities want it from
you. I am sure, often, monitoring reports are not even
read. There should be more trust that we help data
quality and therefore, also help the answer to the
study question”. (Monitor II)
“I always tried to make them feel like I am their
partner, and not some teacher or something…I don’t
want to point the finger at them, but build a
trustworthy relationship so that people at the site
know they can trust me. So that they know they can
call me if there is a problem. (…) The aim is to make
them understand that we are partners and try to help
to get to a good result that all of us do a good job, and
that patients are safe and their rights are protected”.
(Monitor III)
Discussion
As far as we are aware, this is the first mixed methods
study to retrospectively investigate the outcome of on-
site risk-based monitoring according to the ADAMON
framework with regards to patient rights, safety and
data quality in a sample of 43 interventional and obser-
vational studies in the academic setting. We identified a
proportionate amount of patient rights and administra-
tive findings, while findings concerning patient safety
were rare, resulting in costs per documented finding of
US$166. While administrative findings naturally pre-
dominantly occurred at the beginning of the studies
(e.g. at initiation visit), patient rights findings developed
proportionately with the proceeding enrolment of pa-
tients in the study.
Based on our study sample we found in exploratory in-
vestigation factors such as observational study design,
industry sponsorship, a high risk classification, and the
inclusion of a vulnerable study population to be associ-
ated with fewer findings during on-site visits. Surpris-
ingly, a high risk category per se and the inclusion of
vulnerable study populations, which come with an in-
creased frequency of on-site monitoring visits according
to ADAMON, do not cause a larger number of total
findings. Counterintuitively, high risk studies therefore
seem to be at lower risk for poor quality, probably due
to the more closely monitored regulatory and legal en-
vironment which supports a well-planned set up of the
study. It is therefore questionable whether the current
monitoring scheme according to pre-set risk factors will
be effective, both for quality and cost of trials, unless we
learn from these findings. An alternative approach could,
for example, be “experience-based” in the sense that mon-
itoring frequency and extent are continuously adapted
after on-site visits depending on the findings that have
occurred. This would certainly allow for more flexible
monitoring strategies when and where on-site visits are
actually needed in line with current “quality-by-design”
initiatives [22–24]. Practically however, changes in con-
tracts are often difficult after monitoring plans have been
written and budgets have been allocated.
Further, our results are in line with a systematic review
of risk-based monitoring tools which states that both
ADAMON as well as the SCTO guideline do not assess
all 12 fundamental risk indicators as described in the re-
cently published risk indicator taxonomy for supervision
of clinical trials on medicinal products [25, 26]. While
ADAMON lacks indicators on professionalism, reputa-
tion, and level of experience of investigator, clinical trial
site, and sponsor, the SCTO guideline provides indica-
tors assessing the level of experience at least to some
extent [26]. We show that the two of the three risk mod-
ulators that the CTU has used to adjust monitoring ex-
tent purely based on experience with previous studies,
i.e. the absence of an electronic data capture system and
the lack of experience of a site, are clearly associated
with a higher number of findings. This was exemplified
by the two observational outlier studies. These factors
should therefore be considered not only in the modula-
tion of the extent of monitoring, but also influence the
frequency of on-sites visits.
Our qualitative enquiry highlighted that the involved
monitors understand the positive aspects of a risk-based
approach in the resource constrained academic setting,
but fear to miss systematic errors or even patient right
violations due to the low frequency of visits or the lack
of a requirement for initiation visits in low risk studies.
They stressed the importance of well trained, motivated
and experienced trial personnel, i.e. the investigator,
study nurses, and related site staff, for overall trial
quality and success. They further exemplified that these
human factors should play a larger role in the risk evalu-
ation, and that ADAMON does not cover these aspects
adequately. The additional factors that were mentioned
to be crucial for trial quality and success predominantly
covered the design of the study, including how well the
practical aspects of the study are planned, and factors
related to the functioning of the site, such as training
and experience of personnel, planning of finances and
infrastructure, resources, and recruitment, trial coord-
ination and management, assignment of clear responsi-
bilities and transparent communication. While some of
these aspects covered by ADAMON, none of them has
an influence on the final monitoring risk category. We
therefore encourage to put more emphasis on site-related
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and personnel-related risk factors in the risk evaluation of
any studies, both industry- and investigator initiated, in
addition to any framework used.
The initial concept of risk-based monitoring aimed at
optimizing the use of scarce resources while assuring pa-
tient rights and safety as well as data quality in accordance
with the GCP guideline. Several years later, cornerstones
of the risk-based monitoring concept, such as ADAMON
and OPTIMON [8, 20], are still under evaluation and
evidence on the effectiveness and cost savings of this
approach in different host organizations, sponsors, set-
tings, or trial designs remains relatively sparse [27, 28].
There is, however, emerging consensus that 100% SDV
and dual entry procedures are time and cost inefficient
in detecting data discrepancies [17, 29, 30], that some
types of errors in a clinical trial are more important
than others [6], and that a site monitoring approach
tailored to the risk of the trial can be supported in
order to detect critical issues [7, 8, 31]. With our ap-
proach, we mainly identified patient rights and admin-
istrative findings, for which we were not able to
retrospectively judge how critical they were. Our moni-
tors, however, clearly stated the fear of missing system-
atic data errors and even critical issues concerning
patient rights during the on-site visits, which are re-
stricted in frequency and extent by academic financial
constraints, or a low risk category. We thus see a need
for complementary quality assurance measures for sys-
tematic data errors that can be performed off-site, such
as central data verification..
Recently, combinations of central data verification (e.g.
patient rights and safety) and on-site monitoring strat-
egies have been applied to improve the efficiency of risk-
based procedures [5, 7, 32]. Compared to other tools,
ADAMON does only provide vague guidance on the na-
ture and extent of centralized monitoring, while the
adapted form by the Swiss Clinical Trial Organization
recommends that protocol compliance could be moni-
tored centrally for low-risk trials, as described in a re-
cent systematic review by Hurley et al. [26]. According
to the FDA’s recommendations on risk-based monitoring
for industry and the current integrated addendum to
ICH-GCP, centralized monitoring processes could pro-
vide additional capabilities to on-site monitoring in the
academic setting, thereby dispelling our monitor’s
doubts on missing systematic data errors [3, 9]. Statis-
tical monitoring methods are an area of active research
and have been suggested to “help improve the effective-
ness of on-site monitoring by prioritizing site visits and
by guiding site visits with central statistical data
checks” [32] and were shown to identify the great ma-
jority of on-site monitoring findings [7]. In line with
our results, Tudur Smith et al. have recently described
such an approach in non-commercial studies, allowing
for “triggered”, rather than predominantly “routine” on-
site visits [5]. However, empirical data on its effective-
ness and the costs, advantages and disadvantages of
alternative methods are still missing. With central mon-
itoring strategies allowing for efficient data quality
checks, monitors would then also be more flexible to
transform their roles from “controllers” towards “part-
ners”, as they had mentioned in the interviews, and
contribute to overall clinical research quality rather
than mere GCP-conformance.
We are aware of a number of limiting factors in our
analysis as follows. First of all, the retrospective design
of our study did not allow standardization of extracted
data across studies and monitors. Our sample was
heterogeneous in terms of study type, study design,
intended sample size and the risk categorization. It may
further not be entirely representative in type and size of
all studies conducted at out institution, as we predom-
inantly monitor investigator-initiated studies. However,
we aimed to minimize selection bias by including all
trials monitored by the CTU within a given time
period. Second, due to the small sample size and large
heterogeneity of studies, we did not perform multivari-
able analysis but summarized absolute numbers of find-
ings descriptively. Third, these studies were monitored
by six different monitors with varying degree of experi-
ence and over a period of two years. In spite of a stan-
dardized procedure, each monitor has his or her own
personal monitoring style, different level of attention to
detail and strive for perfection. These factors could
have influenced their interactions with the study team,
generation and documentation of monitoring related
findings. Fourth, we could only interview three of these
six monitors who continue to work at our institution.
We are fully aware that their experience and perspec-
tive cannot be generalized but their perspective is crit-
ical in understanding the challenges in effective
monitoring and ways to improve monitoring process.
Furthermore, perspectives of additional stakeholders in-
volved in risk-based monitoring (e.g. trial project
leaders or principal investigators) should be considered
in the future. Finally, we want to discuss the subjective
and flexible nature of risk classification (e.g. risk com-
pared to standard treatment, judging the experience of
staff at a study site and adjustments to available bud-
gets) and diversity in monitoring style of different mon-
itors and their documentation practice. This could have
contributed to an unknown number of findings that
were resolved directly on-site without documentation
and hence out of scope of current analysis. In addition,
we were unable to calculate number of findings in rela-
tion to number of patients recruited due to inconsistent
documentation of number of patients monitored during
each monitoring visit.
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However, by publishing our experiences, we are
supporting an ancillary recommendation made by the
Clinical Trials Transformation Initiative (CTTI) project
on effective and efficient monitoring to “share know-
ledge and experiences, so that best practices may be
established” [33]. The hurdles that we experienced in
the generation of urgently needed evidence on effect-
iveness of monitoring strategies have provided food for
thought as follows: Our study illustrates that while the
very concept of the current risk-based approach allows
for flexibility in tailoring monitoring to the requirements
of a specific study, it may also be prone to ambiguity. The
lack of a “one-fits-all” model may lead stakeholders to be
at loss to define a relevant trial-specific monitoring strat-
egy. We realized that the combination of flexibility in de-
signing the monitoring approach and the subjectivity and
individual preferences of monitors in documenting find-
ings add to the complexity of analyzing the effectiveness
of risk-based approaches. For instance, the change of
monitor in a project was often associated with a specific
findings pattern (e.g. an increase in findings), which may
be explained by preferences regarding the individual docu-
mentation style, the level of detail monitored, or the moni-
tor’s experience. This haziness including the inter-human
and inter-institutional variability should receive more rec-
ognition in the field when investigating the effectiveness
of risk-based approaches in the academic setting.
Finally, we perceive that all of the efforts invested so far
focus on optimizing the cost-effectiveness of current strat-
egies, i.e. assuring patient’s rights and safety as well as data
quality in accordance with the requirements of ICH-GCP.
Interestingly, none of the efforts has so far questioned the
real impact of current monitoring activities in increasing
the overall quality of academic clinical studies. In line with
other authors we believe that the current detection of
non-critical findings adds only little to overall study
quality, while consuming significant resources that
could be spent in areas known to be critical for suc-
cessful trial conduct [17]. For instance, empirical data
show that academic clinical research in particularly suf-
fers from major hurdles in the recruitment of patients,
with recruitment failure being the main reason for early
discontinuation of trials [34–38]. According to a report
by the Tufts Center for the Study of Drug Develop-
ment, about 50% of sites fail to reach the planned re-
cruitment targets and more than 95% of clinical trials
do not end on time and on budget as planned in the
first place. Ninety percent of the studies meet their re-
cruitment goals, but at the expense of mostly twice as
much time as originally planned [39]. Often, this is due
to too many avoidable protocol amendments, with a
first amendment implemented even before the very first
patient has been enrolled [40]. Almost half of the
protocol amendments are considered “somewhat” or
“completely” avoidable [39]. The European Clinical Re-
search Infrastructure Network (ECRIN) hence provides
a broad definition of monitoring as activities which
must be “understood as all onsite and central activities
dealing with checks of data and procedures as well as
with the overall surveillance and stimulation of the trial
progress” [41]. The interviewed monitors have sup-
ported such a holistic approach starting with their in-
volvement in protocol development and processes
based on trial procedures rather than data points per
se, supporting overall trial completion with conclusive
results. In accordance with ICH-GCP E6 R(2), we envi-
sion the future monitor to be an on-site partner to the
study team, supported by centralized data checks adapt-
able to the risk of a trial, considering the experience of
and the management at the site itself [3].
Conclusion
In conclusion, we show that the factors which mostly in-
creased the risk for on-site monitoring findings are under-
represented in the current ADAMON scheme, but have
partly been considered by our monitors based on their
professional experience. We believe that the “human
factor” has been underestimated in the evaluation of risk-
based approaches so far, and should receive more recogni-
tion in the future. In line with recent developments, our
risk-based on-site monitoring should be complemented
by centralized data checks in the future, allowing monitors
to transform their role towards partners for overall trial
quality, and success. However, evidence on the method-
ology and the (cost-) effectiveness of different combina-
tions of the two approaches is still sparse for the academic
setting. Future research should therefore address urgently
needed strategies for efficient and effective monitoring,
based on the current knowledge on risk factors in the aca-
demic setting.
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